Drug intelligence / Profile preview

aponormil

Development stage: Unknown
Lead developer: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Modality: Small Molecules
Administration: Oral

Overview

Aponormil is a herbal phytoconcentrate developed and manufactured by the Ukrainian company Ekomed. It is a water-alcohol extract of medicinal plants marketed as a dietary supplement for supportive care in patients with neoplasms. The product is designed to normalize metabolic processes and enhance the body's resistance to tumor growth, although it lacks a defined molecular mechanism of action. It is typically used as an adjunct to conventional oncological therapies to improve patient well-being and support immune function. The supplement is part of a broader line of phytoconcentrates produced by Ekomed that are widely available in the Ukrainian market.

Brand names: AponormilАпонорміл
Other names: Aponormil phytoconcentrate

Beyond the preview

Go deeper on aponormil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on aponormil.

Explore the full profile